세계의 간염 치료제 시장 보고서(2025년)

Hepatitis Drugs Global Market Report 2025

US $ 4,490 ￦ 6,151,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,891,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,632,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

간염 치료제 시장 규모는 향후 몇 년동안 안정적인 성장세를 보이며 2029년까지 연평균 4.2%의 성장률을 기록해 247억 6,000만 달러에 이를 것으로 예상됩니다. 예측 기간 동안의 성장은 새로운 직접 작용 항바이러스제의 도입, 간염 감염 유병률 증가, 간염 예방 및 치료에 대한 정부 이니셔티브 증가, 간염에 대한 개인 맞춤형 의료 접근법의 발전, 개발도상국에서의 간염 치료제에 대한 접근성 확대 등에 기인할 것으로 보입니다. 예측 기간 동안 주요 동향으로는 인터페론 기반 치료에서 무인터페론 치료로의 전환, C형 간염에 대한 범유전자형 항바이러스제 개발, 간섬유화 평가를 위한 비침습적 진단 방법의 통합, B형 간염에 대한 병용요법 모색, 공중보건 위협으로서의 바이러스성 간염 퇴치에 대한 관심 증가 등이 있습니다. 바이러스성 간염 퇴치에 대한 관심 증가 등을 들 수 있습니다.

다양한 유형의 간염 환자 증가는 간염 치료제 시장의 성장을 크게 촉진하고 있습니다. 다양한 유형의 간염이 서로 다른 치료제를 필요로 하기 때문에 간염 치료제 수요가 증가하고 있습니다. 예를 들어, 스위스에 본부를 둔 국제 공중보건기구인 세계보건기구(WHO)에 따르면, 2022년 6월 기준 2억 9,600만 명이 만성 B형 간염에 감염되어 있으며, 매년 평균 150만 명이 새롭게 감염되고 있습니다. 이러한 간염 감염자 증가는 간염 치료제의 필요성과 소비량을 증가시킵니다. 따라서, 다양한 유형의 간염 증가는 예측 기간 동안 간염 치료제의 성장을 가속할 것으로 예상됩니다.

연구개발에 대한 투자 증가는 향후 몇 년동안 간염 치료제 시장의 성장을 가속할 것으로 예상됩니다. 연구개발은 새로운 제품, 프로세스, 서비스를 발견, 실험, 발명, 개발하거나 기존 제품을 개선하기 위해 기업, 기관, 조직이 수행하는 연구 활동을 말합니다. 연구개발에 대한 투자는 재정적 성장, 사회적 개선, 기업의 성공, 지속가능성에 크게 기여하며, 여러 분야의 발전과 창의성을 촉진합니다. 예를 들어, 2023년 5월 호주 정부의 최고 입법부인 호주 의회에 따르면, 정부는 2022-2023년 R&D에 121억 달러를 투자할 계획입니다. 이는 전년 대비 3.2% 증가한 수치입니다. 따라서 연구개발에 대한 투자 증가가 간염 치료제 시장을 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장-금리, 인플레이션, 지정학, 코로나재난, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 간염 치료제 시장 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
• 최종 이용 산업 분석
• 세계의 간염 치료제 시장 성장률 분석
• 세계의 간염 치료제 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 간염 치료제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 간염 치료제 유효 시장(TAM)

제6장 시장 세분화

• 세계의 간염 치료제 시장 : 약제 클래스별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• Interferon Alphas
• HIV NRTIs
• Nucleotide Polymerase Or NS5A Inhibitor Combinations
• Hepatitis C Protease Or NS5A Inhibitor Combinations
• NS5A Inhibitors
• Nucleotide Polymerase Inhibitors
• Nucleoside Analogue Antivirals
• Thrombopoiesis Stimulating Agents
• 세계의 간염 치료제 시장 : 투여 경로별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 경구
• 주사
• 세계의 간염 치료제 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 간염 치료제 시장 : 용도별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• A형 간염
• B형 간염
• C형 간염
• D형 간염
• E형 간염
• 세계의 간염 치료제 시장 : 인터페론 알파 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 페그인타페론아르파
• 비페그화 인터페론 알파
• 세계의 간염 치료제 시장 : HIV NRTI 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• Zidovudine
• Lamivudine
• Abacavir
• Tenofovir
• 세계의 간염 치료제 시장 : 뉴클레오티드 중합효소 또는 NS5A 억제제 조합 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• Sofosbuvir Or velpatasvir
• Sofosbuvir Or ledipasvir
• 세계의 간염 치료제 시장 : C형 간염 프로테아제 또는 NS5A 억제제 조합 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• Glecaprevir Or pibrentasvir
• Paritaprevir Or ombitasvir Or dasabuvir
• 세계의 간염 치료제 시장 : NS5A 억제제 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• Daclatasvir
• Ledipasvir
• Velpatasvir
• 세계의 간염 치료제 시장 : 뉴클레오티드 중합효소 억제제 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• Sofosbuvir
• Dasabuvir
• 세계의 간염 치료제 시장 : 뉴클레오티드 아날로그 항바이러스제 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• Adefovir
• Entecavir
• Lamivudine
• 세계의 간염 치료제 시장 : 혈전 형성 촉진제 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• Eltrombopag
• Romiplostim

제7장 지역별/국가별 분석

• 세계의 간염 치료제 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 간염 치료제 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 간염 치료제 시장 : 경쟁 구도
• 간염 치료제 시장 : 기업 개요
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• Abbott Laboratories
• AbbVie Inc.
• Arbutus Biopharma Corporation
• Aspen Pharmacare Holdings Limited
• Aurobindo Pharma Limited
• Beximco Pharmaceuticals Ltd.
• Biocon Limited
• Bristol-Myers Squibb Company
• Cadila Healthcare Limited
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Enanta Pharmaceuticals Inc.
• Hetero Drugs Limited
• Laurus Labs Limited
• Lupin Pharmaceuticals Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 시장 최근 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 간염 치료제 시장(2029년) - 가장 새로운 기회를 제공하는 국가
• 간염 치료제 시장(2029년) - 가장 새로운 기회를 제공하는 부문
• 간염 치료제 시장(2029년) - 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Hepatitis drugs refer to medications that aggravate liver inflammation. A number of viruses (viral hepatitis), substances, medications, alcohol, certain genetic abnormalities, an overactive immune system that mistakenly assaults the liver (autoimmune hepatitis), and other factors can result in liver inflammation.

The main type of hepatitis drugs interferon alphas, HIV NRTIS, nucleotide polymerase / NS5A inhibitor combinations, hepatitis C protease / NS5A inhibitor combinations, NS5A inhibitors, nucleotide polymerase inhibitors, nucleoside analog antivirals, and thrombopoiesis stimulating agents. The interferon alphas are the innate immune system in response to environmental exposures such as viral infections. Interferon alpha has been developed in different formulations for the treatment but mainly for chronic hepatitis C. The drugs are consumed through oral or injection route of administration and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. These drugs are used to treat hepatitis A, hepatitis B, hepatitis C, hepatitis D and hepatitis E.

The hepatitis drugs market research report is one of a series of new reports from The Business Research Company that provides hepatitis drugs market statistics, including hepatitis drugs industry global market size, regional shares, competitors with a hepatitis drugs market share, detailed hepatitis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis drugs industry. This hepatitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis drugs market size has grown steadily in recent years. It will grow from $20.04 billion in 2024 to $20.98 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to discovery of antiviral drugs targeting hepatitis viruses, advances in diagnostic technologies for hepatitis, growing awareness of The global burden of hepatitis, expansion of hepatitis vaccination programs, development of interferon-basedTherapies for hepatitis.

The hepatitis drugs market size is expected to see steady growth in the next few years. It will grow to $24.76 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to introduction of novel direct-acting antiviral drugs, increasing prevalence of hepatitis infections, rise in government initiatives for hepatitis prevention and treatment, advances in personalized medicine approaches for hepatitis, expansion of access to hepatitis drugs in developing countries. Major trends in the forecast period include transition from interferon-based to interferon-free therapies, development of pan-genotypic antiviral drugs for hepatitis c, integration of non-invasive diagnostic methods for liver fibrosis assessment, exploration of combination therapies for hepatitis b, growing focus on the elimination of viral hepatitis as a public health threat.

The increase in number of cases of different types of hepatitis is significantly driving the growth of the hepatitis drug market. Various types of hepatitis need different drugs for treatment, which increases the demand for hepatitis drugs. For instance, in June 2022, according to the World Health Organization (WHO), a Switzerland based international public health organization, 296 million people had a chronic hepatitis B infection, with an average of 1. 5 million new infections every year. This increasing number of hepatitis infections will invariably increase the need for and consumption of hepatitis drugs. Thus, the increasing number of different types of hepatitis is expected to propel the growth of hepatitis drugs in the forecast period.

The rising investment in research and development is expected to propel the growth of the hepatitis drug market in the coming years. Research and development refer to the research operations carried out by businesses, institutions, or organizations to discover, experiment, invent, and develop new goods, processes, or services, or to enhance current ones. Investments in research and development contribute considerably to financial growth, societal improvement, corporate success, and sustainability, promoting advancement and creativity in several areas. For instance, in May 2023, according to the Parliament of Australia, an Australia-based government supreme legislative branch, the government is going to invest $12. 1 billion in research and development in 2022-23. This is a 3. 2% increase over the previous year. Therefore, the rising investment in research and development is driving the hepatitis drugs market.

Leading companies in the hepatitis drugs market are concentrating on developing innovative formulations to enhance treatment efficacy, improve patient compliance, minimize side effects, and address the various strains of the hepatitis virus. The FDA Fast Track designation is a process aimed at accelerating the development and review of drugs that treat serious conditions and fulfill an unmet medical need. Medications granted this designation are intended to help patients access new therapies more swiftly, particularly for serious or life-threatening diseases. For example, in February 2024, GSK plc, a UK-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) Fast Track designation for its drug bepirovirsen, aimed at treating chronic hepatitis B (CHB). This designation is significant as it seeks to expedite the development and review process for therapies addressing unmet medical needs in serious conditions.

Major companies operating in the hepatitis drug market are focusing on innovative products, such as Vemlidy (tenofovir alafenamide), to better meet the needs of their existing consumers. Vemlidy (Tenofovir alafenamide) is an antiretroviral medicine belonging to the nucleotide reverse transcriptase inhibitor (NRTI) class used to treat HIV (Human Immunodeficiency Virus) and persistent hepatitis B virus infections. For instance, in November 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced the approval of Vemlidy (tenofovir alafenamide) at a dose of 25 mg for the treatment of chronic hepatitis B virus infection in pediatric individuals. Vemlidy is a new, targeted tenofovir prodrug used as a once-daily therapy for individuals with persistent HBV infection with compensatory liver disease. It is indicated as a recommended or first-line therapy for individuals with chronic HBV and aggravated liver disease in AASLD and EASL recommendations.

In November 2022, Merck & Co., a US-based healthcare company, acquired Imago BioSciences for an undisclosed amount. This acquisition is aimed at enhancing Merck's oncology portfolio by integrating Imago BioSciences' innovative treatments for blood disorders, particularly the LSD1 inhibitor bomedemstat, which shows potential in treating various hematological malignancies. This move is expected to strengthen Merck's capabilities in addressing unmet medical needs. Imago BioSciences is a US-based clinical-stage biotechnology company focused on developing therapies for hematologic diseases.

Major companies operating in the hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Abbott Laboratories, AbbVie Inc., Arbutus Biopharma Corporation, Aspen Pharmacare Holdings Limited, Aurobindo Pharma Limited, Beximco Pharmaceuticals Ltd., Biocon Limited, Bristol-Myers Squibb Company, Cadila Healthcare Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Enanta Pharmaceuticals Inc., Hetero Drugs Limited, Laurus Labs Limited, Lupin Pharmaceuticals Inc., Micro Labs Limited, Mylan N. V., Natco Pharma Limited, Novartis International AG, Roche Holding AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Vir Biotechnology Inc., Genentech Inc., Eisai Pharmaceuticals India Pvt. Ltd.

North America was the largest region in the hepatitis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hepatitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The hepatitis drugs market consists of sales of ribavirin, elbasvir-grazoprevir, and glecaprevir-pibrentasvir. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatitis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Interferon Alphas; HIV NRTIs; Nucleotide Polymerase Or NS5A Inhibitor Combinations; Hepatitis C Protease Or NS5A Inhibitor Combinations; NS5A Inhibitors; Nucleotide Polymerase Inhibitors; Nucleoside Analogue Antivirals; Thrombopoiesis Stimulating Agents
• 2) By Route Of Administration: Oral; Injection
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Hepatitis E
• Subsegments:
• 1) By Interferon Alphas: Pegylated Interferon Alpha; Non-Pegylated Interferon Alpha
• 2) By HIV NRTIs: Zidovudine; Lamivudine; Abacavir; Tenofovir
• 3) By Nucleotide Polymerase Or NS5A Inhibitor Combinations: Sofosbuvir Or velpatasvir; Sofosbuvir Or ledipasvir
• 4) By Hepatitis C Protease Or NS5A Inhibitor Combinations: Glecaprevir Or pibrentasvir; Paritaprevir Or ombitasvir Or dasabuvir
• 5) By NS5A Inhibitors: Daclatasvir; Ledipasvir; Velpatasvir
• 6) By Nucleotide Polymerase Inhibitors: Sofosbuvir; Dasabuvir
• 7) By Nucleoside Analogue Antivirals: Adefovir; Entecavir; Lamivudine
• 8) By Thrombopoiesis Stimulating Agents: Eltrombopag; Romiplostim
• Companies Mentioned: Gilead Sciences Inc.; F. Hoffmann-La Roche Ltd; GlaxoSmithKline plc; Johnson & Johnson; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hepatitis Drugs Market Characteristics

3. Hepatitis Drugs Market Trends And Strategies

4. Hepatitis Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hepatitis Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hepatitis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hepatitis Drugs Market Growth Rate Analysis
• 5.4. Global Hepatitis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hepatitis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hepatitis Drugs Total Addressable Market (TAM)

6. Hepatitis Drugs Market Segmentation

• 6.1. Global Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferon Alphas
• HIV NRTIs
• Nucleotide Polymerase Or NS5A Inhibitor Combinations
• Hepatitis C Protease Or NS5A Inhibitor Combinations
• NS5A Inhibitors
• Nucleotide Polymerase Inhibitors
• Nucleoside Analogue Antivirals
• Thrombopoiesis Stimulating Agents
• 6.2. Global Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injection
• 6.3. Global Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis A
• Hepatitis B
• Hepatitis C
• Hepatitis D
• Hepatitis E
• 6.5. Global Hepatitis Drugs Market, Sub-Segmentation Of Interferon Alphas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pegylated Interferon Alpha
• Non-Pegylated Interferon Alpha
• 6.6. Global Hepatitis Drugs Market, Sub-Segmentation Of HIV NRTIs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Zidovudine
• Lamivudine
• Abacavir
• Tenofovir
• 6.7. Global Hepatitis Drugs Market, Sub-Segmentation Of Nucleotide Polymerase Or NS5A Inhibitor Combinations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sofosbuvir Or velpatasvir
• Sofosbuvir Or ledipasvir
• 6.8. Global Hepatitis Drugs Market, Sub-Segmentation Of Hepatitis C Protease Or NS5A Inhibitor Combinations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glecaprevir Or pibrentasvir
• Paritaprevir Or ombitasvir Or dasabuvir
• 6.9. Global Hepatitis Drugs Market, Sub-Segmentation Of NS5A Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Daclatasvir
• Ledipasvir
• Velpatasvir
• 6.10. Global Hepatitis Drugs Market, Sub-Segmentation Of Nucleotide Polymerase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sofosbuvir
• Dasabuvir
• 6.11. Global Hepatitis Drugs Market, Sub-Segmentation Of Nucleoside Analogue Antivirals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adefovir
• Entecavir
• Lamivudine
• 6.12. Global Hepatitis Drugs Market, Sub-Segmentation Of Thrombopoiesis Stimulating Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eltrombopag
• Romiplostim

7. Hepatitis Drugs Market Regional And Country Analysis

• 7.1. Global Hepatitis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hepatitis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatitis Drugs Market

• 8.1. Asia-Pacific Hepatitis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatitis Drugs Market

• 9.1. China Hepatitis Drugs Market Overview
• 9.2. China Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatitis Drugs Market

• 10.1. India Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatitis Drugs Market

• 11.1. Japan Hepatitis Drugs Market Overview
• 11.2. Japan Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatitis Drugs Market

• 12.1. Australia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatitis Drugs Market

• 13.1. Indonesia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatitis Drugs Market

• 14.1. South Korea Hepatitis Drugs Market Overview
• 14.2. South Korea Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatitis Drugs Market

• 15.1. Western Europe Hepatitis Drugs Market Overview
• 15.2. Western Europe Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatitis Drugs Market

• 16.1. UK Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatitis Drugs Market

• 17.1. Germany Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatitis Drugs Market

• 18.1. France Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatitis Drugs Market

• 19.1. Italy Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatitis Drugs Market

• 20.1. Spain Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatitis Drugs Market

• 21.1. Eastern Europe Hepatitis Drugs Market Overview
• 21.2. Eastern Europe Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatitis Drugs Market

• 22.1. Russia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatitis Drugs Market

• 23.1. North America Hepatitis Drugs Market Overview
• 23.2. North America Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatitis Drugs Market

• 24.1. USA Hepatitis Drugs Market Overview
• 24.2. USA Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatitis Drugs Market

• 25.1. Canada Hepatitis Drugs Market Overview
• 25.2. Canada Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatitis Drugs Market

• 26.1. South America Hepatitis Drugs Market Overview
• 26.2. South America Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatitis Drugs Market

• 27.1. Brazil Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatitis Drugs Market

• 28.1. Middle East Hepatitis Drugs Market Overview
• 28.2. Middle East Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatitis Drugs Market

• 29.1. Africa Hepatitis Drugs Market Overview
• 29.2. Africa Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatitis Drugs Market Competitive Landscape And Company Profiles

• 30.1. Hepatitis Drugs Market Competitive Landscape
• 30.2. Hepatitis Drugs Market Company Profiles
  • 30.2.1. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hepatitis Drugs Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. AbbVie Inc.
• 31.3. Arbutus Biopharma Corporation
• 31.4. Aspen Pharmacare Holdings Limited
• 31.5. Aurobindo Pharma Limited
• 31.6. Beximco Pharmaceuticals Ltd.
• 31.7. Biocon Limited
• 31.8. Bristol-Myers Squibb Company
• 31.9. Cadila Healthcare Limited
• 31.10. Cipla Limited
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Enanta Pharmaceuticals Inc.
• 31.13. Hetero Drugs Limited
• 31.14. Laurus Labs Limited
• 31.15. Lupin Pharmaceuticals Inc.

32. Global Hepatitis Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatitis Drugs Market

34. Recent Developments In The Hepatitis Drugs Market

35. Hepatitis Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Hepatitis Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hepatitis Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hepatitis Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료